How is Trump's trade war impacting your mental health?
A daily barrage of 'on again, off again' tariff headlines, and threats to Canadian sovereignty.
What impact is all the Trump turbulence having on your mental health?
Join Ian Hanomansing on CBC Radio One, CBC Listen and CBC News Network. Call Checkup at 1-888-416-8333, or text 226-758-8924 or go to CBC.ca/aircheck .
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
2 hours ago
- The Market Online
U.S. federal cannabis rescheduling: A game-changer for Canopy Growth?
The U.S. government is considering reclassifying cannabis from Schedule I to Schedule III, which would recognize its medical benefits, ease research restrictions, and offer tax relief to cannabis businesses Through its Canopy USA structure, Canopy Growth holds stakes in major U.S. cannabis companies like Acreage Holdings, Wana Brands, and Jetty, positioning itself to capitalize on federal policy changes Canopy Growth reported a 43 per cent year-over-year increase in Canadian adult-use cannabis revenue in Q1 FY2026, signaling operational momentum as it prepares for potential U.S. market expansion Canopy Growth stock (TSX:WEED) last traded at C$2.08 The United States could be on the cusp of a transformative shift in federal cannabis policy. Recent statements from President Donald Trump and widespread media coverage confirm that the administration is currently reviewing a proposal to reclassify cannabis from a Schedule I to a Schedule III controlled substance. This content has been prepared as part of a partnership with Canopy Growth Corp. and is intended for informational purposes only. This reclassification would mark the most significant federal policy change in over 50 years, formally acknowledging cannabis's medical utility and opening new avenues for research, patient access, and industry growth. Currently, cannabis is classified alongside heroin and LSD under Schedule I, a category reserved for substances with no accepted medical use and high abuse potential. Moving it to Schedule III—alongside drugs like ketamine and anabolic steroids—would signal a federal recognition of its therapeutic potential and reduce regulatory burdens. Implications of Schedule III reclassification If cannabis is reclassified, the following changes are expected: Medical recognition : Cannabis would be federally acknowledged as having medical benefits, aligning U.S. policy more closely with countries like Canada, Germany, and Australia. : Cannabis would be federally acknowledged as having medical benefits, aligning U.S. policy more closely with countries like Canada, Germany, and Australia. Expanded research : Researchers would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers imposed by Schedule I classification. : Researchers would gain broader access to cannabis products for clinical trials, overcoming the restrictive barriers imposed by Schedule I classification. Tax relief: Cannabis businesses would no longer be subject to Section 280E of the IRS tax code, which currently prevents them from deducting ordinary business expenses. This could significantly improve profitability across the sector. Regulatory clarity: While not full legalization, Schedule III status would provide a more stable regulatory environment, encouraging institutional investment and broader market participation. With the U.S. retail cannabis market projected to reach approximately US$50 billion by 2026, the stakes are … high. Canopy Growth: Positioned for U.S. expansion Canopy Growth Corp. (TSX:WEED, NASDAQ:CGC) has positioned itself to capitalize on the evolving U.S. cannabis landscape through its Canopy USA structure. This unconsolidated, non-controlling entity holds a portfolio of U.S. cannabis assets, including: Acreage Holdings, Inc. – A vertically integrated multi-state operator with a strong presence in the Northeast and Midwest. – A vertically integrated multi-state operator with a strong presence in the Northeast and Midwest. Wana Brands – An edibles company. – An edibles company. Jetty (Lemurian, Inc.) – A California-based producer of premium cannabis extracts and vape technology. – A California-based producer of premium cannabis extracts and vape technology. The Cima Group and Wana Wellness – Expanding Canopy's reach into wellness and lifestyle segments. This structure allows Canopy to maintain compliance with U.S. federal regulations while retaining exposure to the upside of U.S. market growth. Shareholders recently approved the creation of a new class of exchangeable shares; a move designed to accelerate Canopy's U.S. market entry and enhance flexibility. Financial momentum and solid readiness Canopy Growth's Q1 FY2026 results reflect a company regaining momentum: Canada adult-use cannabis net revenue rose 43 per cent year-over-year to C$27 million , driven by strong demand for new products like Claybourne infused pre-rolls. rose to , driven by strong demand for new products like Claybourne infused pre-rolls. Total cannabis revenue increased 24% , while consolidated net revenue grew 9 per cent to C$72.1 million . increased , while consolidated net revenue grew to . The company achieved CA$17 million of its CA$20 million annualized cost savings target and reduced SG&A expenses by 21 per cent. CEO Luc Mongeau emphasized the company's focus on high-demand product categories and retail distribution, while interim CFO Tom Stewart highlighted ongoing efforts to improve gross margins and operational efficiency, stating, 'Our financial discipline has already delivered meaningful operating expense reductions, and we see further opportunity to simplify and focus the business. Improving gross margin remains a key priority while maintaining topline performance in all areas of the business.' Investor takeaway: A catalyst for revaluation The potential rescheduling of cannabis to Schedule III could be a major catalyst for Canopy Growth and the broader cannabis sector. For Canopy, it would: Unlock tax savings and improve cash flow. Enable deeper integration of its U.S. assets under Canopy USA. Attract institutional investors previously deterred by regulatory uncertainty. Accelerate revenue growth in the world's largest cannabis market. While regulatory timelines remain uncertain, the momentum is clearly building. For investors, Canopy Growth represents a well positioned, financially disciplined player ready to seize the opportunities of a rescheduled U.S. cannabis market. About Canopy Growth Canopy Growth Corp. delivers products with a focus on premium and mainstream cannabis brands, in addition to vaporizer technology made in Germany. Canopy Growth stock (TSX:WEED) last traded around 8 per cent lower at C$2.08 on the TSX. Though it has risen 10 per cent since June, it has lost 47 per cent since the year began and 78 per cent since this time last year. On the NASDAQ, CGC stock also finished 8 per cent lower at US$1.50. It has risen more than 12 per cent since June but has lost 45 per cent since the year began and is 78 per cent lower since this time last year. Join the discussion: Find out what the Bullboards are saying about Canopy Growth and check out Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here .
Cision Canada
16 hours ago
- Cision Canada
Prescientx Ushers in Canada's New Era of Engineered Infection Prevention
WATERLOO, ON, /CNW/ - As Canadian healthcare facilities face rising disease transmission and new national infection control standards, IPC Technologies Inc. (operating as Prescientx) announces exclusive Canadian healthcare distribution rights for a suite of advanced Engineered Infection Prevention (EIP) technologies. Prescientx is uniquely positioned to help hospitals and healthcare construction partners meet and exceed the new CSA Z8000 and Z317.12 standards—critical for compliance and Ministry of Health funding across several provinces. The new standards address critical vulnerabilities in healthcare: the need for continuous upper air disinfection, continuous surface disinfection, continuous sink disinfection and automatic whole room disinfection. Prescientx's technologies can achieve up to a 100-fold reduction in exposure to pathogens, continuously and automatically, representing a monumental leap in patient and staff safety designed to significantly reduce Healthcare Acquired Infections (HAIs). "The conversation around infection control in Canada has fundamentally changed," said Keith Hunt, President of Prescientx. "It's no longer just about daily disinfection; it's about engineering for continuous protection. The new CSA standards require a level of verifiable, engineered performance – pathogen reduction that provides a cost-benefit that daily disinfection simply cannot provide. Most importantly, they mandate EIP-qualified personnel to advise and oversee these systems. Our entire business is structured to meet this exact moment." Prescientx's exclusive portfolio includes: ASEPT-1X MAX ™ by Sanuvox – A Health Canada PMRA approved engineered patented UVC system for creating fully automated, self-disinfecting rooms in Canada. SmartFLO3 ™ by Franke – A splashless CSA-compliant self-cleaning and disinfecting, biofilm-free sink system, engineered for compatibility with UV disinfection. Sanilume by iLLUMiSoft Lighting – A Health Canada PMRA approved optimized, high-output Upper Air GUV solution, providing continuous air disinfection designed to reduce exposure to airborne pathogens to near zero levels. EOScu surfaces & Aereus copper coatings – self-disinfecting surfaces like overbed tables, countertops, bedrails, fixtures and hardware that rapidly and continually reduce pathogens on epidemiologically important, high touch surfaces. This announcement solidifies the company's strategic business model, which shed its former manufacturing arm to focus exclusively on the professional services and specialized distribution required by today's market. "Our identity has always been rooted in providing automated solutions to reduce Healthcare Acquired Infections through engineering expertise," Hunt added. "Our focused model allows us to be true, unbiased partners to IPAC Professionals, Hospital Contractors, and Facility Managers. We de-risk their projects by ensuring the solutions are not only compliant from day one but are also integrated correctly for long-term reliability and provide a stunning return on investment. We have shown payback periods as short as 23 days." Prescientx urges healthcare stakeholders to assess their readiness for the new CSA standards and explore engineered solutions that deliver continuous protection and measurable outcomes. About Prescientx Inc. Canada.
Globe and Mail
16 hours ago
- Globe and Mail
Eli Lilly hikes price of Mounjaro weight-loss drug in Canada, Britain after pressure from Trump
U.S. drugmaker Eli Lilly & Co. has increased prices of its popular diabetes and anti-obesity drugs in Canada as it responds to pressure from the Trump administration to lower prices in the United States and raise them elsewhere. The company also announced it is sharply raising prices in Britain to match those in other European markets. The moves make the company one of the most high-profile so far to respond U.S. President Donald Trump's direction to rebalance global drug prices. 'Lilly supports the administration's goal of keeping the United States the world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries,' the company said Thursday in an unsigned statement. 'This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the U.S.' Is working out necessary in the age of Ozempic? Lilly is raising the list price in Britain for Mounjaro, its type 2 diabetes treatment, by 170 per cent, Reuters reported. The market for weight-loss drugs has exploded in recent years, led by Novo Nordisk's Ozempic and Wegovy, which are prescribed for diabetes and obesity, respectively. Ozempic earned $2.5-billion at retail pharmacies in Canada in 2024, according to data from industry broker IQVIA, nearly triple the next best-selling drug. Lilly introduced Mounjaro in Canada in late 2023. It was originally sold in single-dose vials (taken weekly) at a wholesale price of around $80. It is sold in six different dosages. The company then introduced a four-dose format called Kwikpen in January of 2025 and then a Kwikpen form of Zepbound, for obesity, in June. At the same time, it raised the prices of the single-dose vials to be in line with those of the Kwikpen and lowered production of the vials, leading to low inventories across the country. Cubic Health, a company that analyzes drug prices for insurance plan sponsors, said in a recent note to its clients that the annual cost of taking Mounjaro has more than doubled for high dosages since it first came to Canada. Cubic said the wholesale price for the Kwikpen now ranges from $387 to $773 depending on dosage, which can lead to an annual cost of more than $10,000. (Individual costs can vary depending on pharmacy, insurance coverage, discounts and other factors.) 'Vials were only intended as a short-term solution until a multidose pen became available to the Canadian market,' Lilly spokesman Ethan Pigott said in a statement. 'Lilly will continue to support patients already using the vial format, but the KwikPen device will be prioritized go-forward for its supply sustainability, ease of use and multidose presentation.' He also said discussion of price should include multiple factors. 'Both Mounjaro and Zepbound are priced to reflect the value they can provide to individuals, health systems, and society in treating type 2 diabetes and obesity,' Mr. Pigott said. Mounjaro and Zepbound are covered by some private insurance plans, depending on individual plan designs. The drugs are not yet covered by any public insurance plans, which require going through national bodies that assess drugs and negotiate prices. Lilly had started an application to Canada's Drug Agency to have Mounjaro (also known as tirzepatide) assessed in 2022, but a spokesperson for the CDA said the submission was cancelled because of paperwork deficiencies. Earlier: Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers Mr. Pigott said Lilly is finalizing plans to resubmit Mounjaro, along with Zepbound, to the CDA 'in 2025.' While the average cost of these drugs in Canada is up, it is still a little short of prices in the U.S. The wholesale price of Zepbound in the U.S. is US$1,086, according to Lilly's website. It also offers direct-to-consumer sales in the U.S. at prices that range from US$349 to US$1,049, depending on dosage. Lilly has not yet launched direct sales in Canada. Drug prices in the U.S. are, on average, more than three times those in Canada. Mr. Trump has repeatedly mentioned that statistic as he admonishes drug companies for their prices. In May, he signed an executive order that directed Health Secretary Robert F. Kennedy Jr. to work with drug companies on 'most favoured nation' pricing for pharmaceuticals. Trump says new order will lower U.S. drug prices and increase them everywhere else Two weeks ago, Mr. Trump sent letters to 17 drug companies – including Lilly – telling them to increase prices in non-U.S. markets to make up for lower revenue in the U.S. The administration has also launched a national-security investigation of the sector that could lead to tariffs, which Mr. Trump has mused could be as high as 200 per cent. In Lilly's statement on Thursday, the company said it does not support tariffs. 'Broad tariffs would raise costs, limit patient access and undermine American leadership, especially for companies already investing heavily in domestic manufacturing,' the company said.
